Pediatric pharmacogenomics: a systematic assessment of ontogeny and genetic variation to guide the design of statin studies in children.

Creator(s)

Jonathan B. Wagner, Children's Mercy HospitalFollow
J Steven Leeder, Children's Mercy HospitalFollow

Document Type

Article

Publication Date

10-1-2012

Identifier

PMCID: PMC5847265 DOI: 10.1016/j.pcl.2012.07.008

Abstract

The dose-exposure-response relationship for drugs may differ in pediatric patients compared with adults. Many clinical studies have established drug dose-exposure relationships across the pediatric age spectrum; however, genetic variation was seldom included. This article applies a systematic approach to determine the relative contribution of development and genetic variation on drug disposition and response using HMG-CoA reductase inhibitors as a model. Application of the approach drives the collection of information relevant to understanding the potential contribution of ontogeny and genetic variation to statin dose-exposure-response in children, and identifies important knowledge deficits to be addressed through the design of future studies.

Journal Title

Pediatric clinics of North America

Volume

59

Issue

5

First Page

1017

Last Page

1037

MeSH Keywords

Adult; Child; Cholesterol, LDL; Dose-Response Relationship, Drug; Dyslipidemias; Genetic Variation; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pediatrics; Pharmacogenetics; Research Design

Comments

Grant support

• T32 HD069038/HD/NICHD NIH HHS/United States

Recommended Citation

Wagner, J. B., Leeder, J. Pediatric pharmacogenomics: a systematic assessment of ontogeny and genetic variation to guide the design of statin studies in children. Pediatric clinics of North America 59, 1017-1037 (2012).